Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00049231 · ClinicalTrials.gov registry record · NA

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

A NA study of Cervical Cancer, sponsored by Gynecologic Oncology Group.

Completed
Registry status
NA
Development phase
5
Study locations

NCT00049231 is a NA study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00049231, a NA study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
NA
Development phase
5
Study locations

Study Summary

RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in detecting tumor hypoxia in patients who have stage IIB, stage IIIB, or stage IVA cervical cancer.

Conditions Studied

Interventions

  • PROCEDURE biopsy
  • OTHER immunohistochemistry staining method
  • DRUG EF5

Study Locations (5)

Oklahoma

  • Oklahoma University Medical Center - Oklahoma City
  • Cancer Care Associates - Midtown Tulsa - Tulsa

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Colorado

  • Colorado Gynecologic Oncology Group P.C. - Denver

Missouri

  • Ellis Fischel Cancer Center at University of Missouri - Columbia - Columbia

Trial Details

FieldValue
Start Date 2003-06
Est. Completion 2005-08
Phase NA

Sponsor

Gynecologic Oncology Group

154 total trials

What the Registry Record Tells You About NCT00049231

The ClinicalTrials.gov registry entry for NCT00049231 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.

NCT00049231 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Oklahoma, Arkansas, Colorado.

Frequently Asked Questions

What is clinical trial NCT00049231 about?

NCT00049231 is a clinical study titled "EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer". RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in de...

What is the current status of trial NCT00049231?

This trial is currently completed. It is a NA study. The study started on 2003-06. Estimated completion is 2005-08.

What conditions does trial NCT00049231 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT00049231?

The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), EF5 (DRUG).

Who is sponsoring clinical trial NCT00049231?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00049231 being conducted?

This trial has 5 study locations across Arkansas, Colorado, Missouri, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.